Investor Relations

5 November 2015

Financial calendar


Upcoming events

Jefferies Global Healthcare Conference, London

Attendance: Management (am)

J.P. Morgan Cazenove 'Best of British' Conference, London

Attendance: Management (am)


Past events



JP Morgan Healthcare Conference

Pascal Soriot, Chief Executive Officer, AstraZeneca presented an update on the company’s development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.


Fostamatinib analyst briefing

Download presentation.

Third quarter and nine months results 2012

Download presentation and analyst call script.

Investor information

Late-stage pipeline progress

Dr Sean Bohen, AstraZeneca’s Executive Vice-President of Global Medicines Development and the Chief Medical Officer, talks about the YTD and Q3 2015 late-stage pipeline progress across our main therapy areas: respiratory diseases, inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology.

Financial results

Total revenue
↑ 4% at CER

Core earnings per share
↓ -8% at CER

Annual Report websites

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.

We have dedicated websites for our 2013 and 2014 Annual Reports.

Investor notes

I/O combo data updated at SITC - durvalumab plus tremelimumab combination data in lung cancer (6 November 2015)

AstraZeneca Investor Relations Team's Briefing Note regarding updated combination data presented at the Society for Immunotherapy in Cancer (SITC) on Friday 6 November 2015.

AstraZeneca refines its financial reporting in line with evolving business model (6 March 2015)

AstraZeneca announced an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors.

Accounting for the US Branded Pharmaceutical Fee (7 January 2015)

In mid 2014 the Internal Revenue Service issued final regulations that affected how the annual branded pharmaceutical fee, imposed by the health care reform legislation in 2010 is recognised. As a result, entities covered by the legislation will now accrue for the obligation as each sale occurs. AstraZeneca recorded a catch-up charge to SG&A, reflecting this new basis, as part of its Q3 2014 results.

Contact us

UK investor enquiries

Main Contacts

UK general enquiries

Thomas Kudsk Larsen


Eugenia Litz

Respiratory, Inflammation & Autoimmunity

Nick Stone

Cardiovascular & Metabolic disease

Craig Marks


Christer Gruvris

Consensus Forecasts

US investor enquiries

Mai contacts

US general enquires

Lindsey Trickett

Oncology; Infection, Neuroscience & Gastrointestinal

Mitch Chan


  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.

  • Shareholder FAQs

    Answers to frequently asked shareholder questions.

  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development